U.S. markets open in 1 hour 15 minutes
  • S&P Futures

    4,378.50
    -33.25 (-0.75%)
     
  • Dow Futures

    34,837.00
    -137.00 (-0.39%)
     
  • Nasdaq Futures

    14,860.00
    -177.75 (-1.18%)
     
  • Russell 2000 Futures

    2,220.60
    -16.90 (-0.76%)
     
  • Crude Oil

    73.43
    -0.19 (-0.26%)
     
  • Gold

    1,831.50
    -4.30 (-0.23%)
     
  • Silver

    25.56
    -0.22 (-0.86%)
     
  • EUR/USD

    1.1895
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    19.18
    +0.87 (+4.75%)
     
  • GBP/USD

    1.3966
    +0.0008 (+0.06%)
     
  • USD/JPY

    109.6600
    +0.1990 (+0.18%)
     
  • BTC-USD

    38,856.48
    -810.41 (-2.04%)
     
  • CMC Crypto 200

    923.40
    -6.96 (-0.75%)
     
  • FTSE 100

    7,019.11
    -59.31 (-0.84%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

·3 min read

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So, the natural question for Relmada Therapeutics (NASDAQ:RLMD) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

View our latest analysis for Relmada Therapeutics

Does Relmada Therapeutics Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Relmada Therapeutics last reported its balance sheet in March 2021, it had zero debt and cash worth US$103m. Importantly, its cash burn was US$40m over the trailing twelve months. That means it had a cash runway of about 2.5 years as of March 2021. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Relmada Therapeutics' Cash Burn Changing Over Time?

Because Relmada Therapeutics isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. In fact, it ramped its spending strongly over the last year, increasing cash burn by 200%. It's fair to say that sort of rate of increase cannot be maintained for very long, without putting pressure on the balance sheet. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Can Relmada Therapeutics Raise More Cash Easily?

Given its cash burn trajectory, Relmada Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Relmada Therapeutics has a market capitalisation of US$581m and burnt through US$40m last year, which is 7.0% of the company's market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

How Risky Is Relmada Therapeutics' Cash Burn Situation?

On this analysis of Relmada Therapeutics' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don't think they should be worried. Taking an in-depth view of risks, we've identified 2 warning signs for Relmada Therapeutics that you should be aware of before investing.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.